ClinicalTrials.gg
RecruitingNCT07140484Updated Nov 5, 2026

Sotatercept in Pulmonary Arterial Hypertension

A Phase 4 interventional study of Sotatercept in Pulmonary Artery Hypertension, sponsored by University of Alberta. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Alberta · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension.

Participants will be asked to:

  • Take Sotatercept every 21 days (±3 days)
  • Each participant will be enrolled in the study for 29 Weeks
  • Visit the clinic 18 times
  • Have a physical exam
  • Perform assessments of lung function and exercise tests
  • Have an ultrasound of their heart
  • Have blood draws done at regular intervals

The main objectives of the study are:

Primary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise.

Secondary objective: To identify components of the diffusing capacity that respond to treatment with sotatercept in pulmonary arterial hypertension.

Read the detailed description

Potential participants must provide their written informed consent before any study-specific procedures.

All screening procedures will be completed over two weeks during three separate visits. For participants from the Calgary site (site 2), all Visit 1 procedures except for PFT and CPET may be performed on a separate day in Calgary. Visits 2 and 3 will be performed in Edmonton (site 1). According to patient preference, visits 2 and 3 can be performed on the same day, with a minimum 3-hour break between visits. For participants from Calgary (site 2), the first drug administration will occur in Calgary within seven days of completion of Visit 3 procedures.

Screening will include reviewing the participant's medical, surgical, and family history, collecting demographics, race, and ethnicity, and requesting medical records for relevant external procedures.

Screening procedures include:

Visit 1:

  • Informed consent
  • Inclusion/exclusion criteria
  • Medical history review
  • Physical examination
  • 12-lead ECG
  • Vital signs
  • Weight
  • WHO FC assessment
  • 6MWT
  • Pregnancy test
  • Hematology (complete blood count)
  • Urinalysis
  • Hemoglobin
  • Serum chemistry
  • NT-proBNP
  • PFT
  • CPET
  • QoL assessments
  • AE/SAE Review
  • Concomitant medication review

Visit 2:

  • Hemoglobin
  • Rest/exercise DLCO, VC, DM
  • Rest/exercise CW-NIRS
  • AE/SAE Review
  • Concomitant medication review

Visit 3:

  • Pregnancy test
  • Rest/exercise Echocardiography
  • AE/SAE Review
  • Concomitant Medication review
  • Study drug administration

Measurements/assessments taken during the Screening Period will be recorded as the baseline values for the study assessment of endpoints.

Treatment Period (Visit 4-14) All study procedures should be performed prior to the study drug administration. For participants at the Calgary site, Visits 4,8-14 occur at their home site. For participants from the Calgary site (site 2), Visit 5-7 will be performed in Edmonton (site 1). Visits 5-7 are to be performed before the administration of the 3rd dose of the study drug. According to the patient's preference, visits 6 and 7 may be combined.

Visit 4 (Week 3)

  • Focused cardiopulmonary physical examination
  • Vital signs
  • Weight
  • WHO FC assessment
  • 6MWT
  • Pregnancy test
  • Hematology
  • Urinalysis
  • Clinical worsening assessment
  • AE/SAE Review
  • Concomitant medication review

Visit 5 (Week 5-6):

  • PFT
  • CPET
  • QoL assessments
  • AE/SAE Review
  • Concomitant medication review

Visit 6 (Week 5-6):

  • Hemoglobin
  • Rest/exercise DLCO, VC, DM
  • Rest/exercise CW-NIRS
  • AE/SAE Review
  • Concomitant medication review

Visit 7 (Week 5-6):

  • Pregnancy test
  • Rest/exercise Echocardiography
  • AE/SAE Review
  • Concomitant Medication review

Visit 8 (Week 6):

  • Focused cardiopulmonary physical examination
  • 6MWT
  • Vital signs
  • Weight
  • WHO FC assessment
  • Pregnancy test
  • Hematology
  • Urinalysis
  • Clinical worsening assessment
  • AE/SAE Review
  • Concomitant medication review

Visit 9 (Week 9):

  • Focused cardiopulmonary physical examination
  • 6MWT
  • 12-lead ECG
  • Vital signs
  • Weight
  • WHO FC assessment
  • Pregnancy test
  • Hematology
  • Serum chemistry
  • NT-proBNP
  • Clinical worsening assessment
  • AE/SAE Review
  • Concomitant medication review

Visit 10-14 (Week 12 - 24):

  • Focused cardiopulmonary physical examination
  • 6MWT
  • Vital signs
  • Weight
  • WHO FC assessment
  • Pregnancy test
  • Hematology
  • Urinalysis
  • Clinical worsening assessment
  • AE/SAE Review
  • Concomitant medication review

End-of-Study Period (Visits 13-14) End-of-Study period visits will start 1 week after the last dose of the study medication and will be completed over 2 weeks. Visits 15-17 will be performed in Edmonton (site 1). Visit 16 and 17 can be performed on the same day according to patient preference.

Visit 15:

  • Weight
  • Hemoglobin
  • PFT
  • CPET
  • QoL Assessment
  • AE/SAE Review
  • Concomitant medication review

Visit 16:

  • Hemoglobin
  • Rest/exercise DLCO, VC, DM
  • Rest/exercise CW-NIRS
  • AE/SAE Review
  • Concomitant medication review

Visit 17:

  • Rest/exercise echocardiography
  • AE/SAE Review
  • Concomitant medication review

Follow-up period (Visit 18) A follow-up visit will occur 3 weeks after the last dose of the study medication. For Edmonton participants (site 1), Visit 18 may happen on the same day after Visit 17 is completed.

Visit 18:

  • 6MWT
  • 12-lead ECG
  • Vital signs
  • WHO FC assessment
  • Pregnancy test
  • Hematology
  • Urinalysis
  • NT-proBNP sample collection
  • Clinical worsening assessment
  • AE/SAE Review
  • Concomitant medication review

Following the last dose of study drug administration, participants have the option to continue with open label sotatercept supplied directly from the manufacturer until either the participant discontinues sotatercept or reimbursement through public or private insurance is in place. The treating physician will be responsible for ongoing monitoring and administration of sotatercept beyond the last dose.

02

Conditions studied

  • Pulmonary Artery Hypertension

Keywords

  • diffusing capacity
  • membrane diffusing capacity
  • pulmonary capillary blood volume
03

In context

Lead sponsor

University of Alberta is the lead sponsor of 825 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligible participants must meet all of the following inclusion criteria to be enrolled in the study:

  1. Age ≥ 18 years.
  2. Documented diagnostic right heart catheterization (RHC) at any time prior to screening confirming the diagnosis of PAH Group 1 in any of the following subtypes:

    • Idiopathic PAH
    • Heritable PAH
    • Drug/toxin-induced PAH
    • PAH associated with CTD
    • PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair.
  3. Symptomatic PAH classified as WHO FC II or III.
  4. On stable doses of ≥2 background PAH therapies for at least 60 days prior to screening; for infusion prostacyclins, dose adjustment within 10% of the optimal dose is allowed per medical practice. Patients on 1 background PAH therapy are eligible if there is documented intolerance or to use of the other 2 classes (e.g. liver enzyme elevation while taking an ERA).
  5. Females of must:

    • Have a negative urine or serum pregnancy tests as verified by the investigator prior to starting study therapy.
    • If sexually active, have used, and agree to use highly effective without interruption during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment.
    • Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment.
  6. Male participants must:

    • Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following product discontinuation, even if he has undergone a successful vasectomy.
    • Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
  7. Ability to adhere to study visit schedule and understand and comply with all protocol requirements.
  8. Ability to understand and provide written .

Exclusion Criteria

  1. 1. Diagnosis of pulmonary hypertension WHO Groups 2, 3, 4, or 5
  2. Musculoskeletal limitation that precludes participation in cycle ergometry
  3. Resting oxygen saturation \< 88%. (Note: patients on oxygen can be included in the study if they can maintain a resting saturation of ≥ 88 % after 3 minutes off oxygen).
  4. Diagnosis of the following PAH Group 1 subtypes: (HIV)-associated PAH and PAH associated with portal hypertension, schistosomiasis-associated PAH and pulmonary veno-occlusive disease.
  5. (Hgb) at screening above the gender-specific (ULN), per local laboratory test.
  6. Baseline count \< 50,000/mm3 (\< 50.0 × 109/L) in the enrollment period.
  7. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mmHg or sitting diastolic blood pressure > 100 mmHg during a screening visit after a period of rest.
  8. Baseline systolic blood pressure \< 90 mmHg at screening.
  9. Pregnant or breastfeeding women.
  10. Any of the following clinical laboratory values at the screening visit:

    • Estimated (eGFR) \< 30 mL/min/m2 (as defined by the Modification of Diet in Renal Disease [MDRD] equation)
    • Serum , aspartate aminotransferase, or total levels > 3 × ULN (bilirubin criterion waived if there is a documented history of Gilbert's syndrome).
  11. Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for biologics prior to the date of signed informed consent.
  12. History of full pneumonectomy.
  13. Pulmonary function test (PFT) values of forced vital capacity (FVC) \< 60% predicted and/or /FVC \< lower limit of normal at the screening visit or within 6 months prior to the screening visit.
  14. Smoking history of ≥ 20 pack-years or any tobacco smoking or vaping within the previous 3 months.
  15. ≥ 40 kg/m2.
  16. Planned initiation of an exercise program for cardiopulmonary rehabilitation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible).
  17. Known history of portal hypertension or chronic liver disease, including and/or (with evidence of recent infection and/or active virus replication), defined as mild to severe hepatic impairment ( Class A-C).
  18. History of restrictive, constrictive, or congestive cardiomyopathy.
  19. History of atrial septostomy within 180 days prior to the screening visit.
  20. (ECG) with Fridericia's interval (QTcF) > 500 ms during the Screening Period
  21. Personal or family history of long QT syndrome (LQTS) or sudden cardiac death.
  22. \< 45% on historical echocardiogram within 6 months prior to the screening visit.
  23. Any symptomatic coronary disease events (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the screening visit. Note: Anginal pain can be ignored as an exclusion criterion if coronary angiography shows no obstructions.
  24. Cerebrovascular accident within 3 months prior to the Screening Visit.
  25. Significant mitral or aortic valve dysfunction (greater than moderate mitral regurgitation or aortic regurgitation, or greater than mild mitral stenosis or aortic stenosis).
  26. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to the screening visit.
  27. Known to sotatercept or to any ingredient in the formulation or component of the container.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Sotatercept Group

    Sotatercept 0.7mg/kg

    Drug: Sotatercept

Interventions

06

What researchers measure

Primary outcomes

  1. Lung diffusing capacity

    Lung diffusing capacity (DLCO) will be measured using six-second, advanced DLCO techniques

    Time frame: 6 weeks post starting treatment

  2. Lung diffusing capacity

    Lung diffusing capacity (DLCO) will be measured using six-second, advanced DLCO techniques

    Time frame: 23 weeks post starting treatment

  3. Diffusing membrane capacity (Dm)

    Diffusing membrane capacity will be measured using six-second, advanced DLCO

    Time frame: 6 weeks post starting treatment

  4. Diffusing membrane capacity (Dm)

    Diffusing membrane capacity will be measured using six-second, advanced DLCO

    Time frame: 23 weeks post starting treatment

  5. Pulmonary capillary blood volume (Vc)

    Pulmonary capillary blood volume (Vc) will be measured using six-second, advanced DLCO techniques

    Time frame: 6 weeks post starting treatment

  6. Pulmonary capillary blood volume (Vc)

    Pulmonary capillary blood volume (Vc) will be measured using six-second, advanced DLCO techniques

    Time frame: 23 weeks post starting treatment

Secondary outcomes

  1. Cardiac structure and function

    Cardiac structure will be measured using standard cardiac ultrasound

    Time frame: 6 weeks post starting treatment

  2. Cardiac structure and function

    Cardiac structure will be measured using standard cardiac ultrasound

    Time frame: 23 weeks post starting treatment

  3. Cardiac function

    Cardiac function will be measured using standard cardiac ultrasound

    Time frame: 6 weeks post starting treatment

  4. Cardiac function

    Cardiac function will be measured using standard cardiac ultrasound

    Time frame: 23 weeks post starting treatment

  5. Peripheral muscle microcirculation

    Peripheral muscle microcirculation will be measured using continuous-wave near-infrared spectroscopy

    Time frame: 6 weeks post starting treatment

  6. Peripheral muscle microcirculation

    Peripheral muscle microcirculation will be measured using continuous-wave near-infrared spectroscopy

    Time frame: 23 weeks post starting treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jan 2029, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 24, 2025
StartActual
Oct 6, 2025
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jan 1, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07140484
Collaborators
Merck Canada Inc., Alberta Health services
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Oct 6, 2025
Primary completion
Jan 1, 2029 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Desi Fuhr, MSc
Contact
fuhr@ualberta.ca
7804921121
Kostia Dmytriiev, MD
Contact
kdmytrii@ualberta.ca
7804928027
Jason Weatherald, MD
principal investigator · University of Alberta
Michael Stickland, PhD
principal investigator · University of Alberta

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion